Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Elvanse®:Takeda Pharma AG
Complete information for professionalsDDDÄnderungen anzeigenPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
PackagesRegistration ownerLast update of information 
N06BA12 - LisdexamfetamineATC-DDD Version 2016. Source: WHO
N - Nervous System
N06 - Psychoanaleptics

This group comprises antidepressants, psychostimulants, nootropics anti-dementia drugs and combinations with psycholeptics.
Antiobesity preparations are classified in A08 - Antiobesity preparations, excl. diet products.

N06B - Psychostimulants, Agents Used for Adhd and Nootropics

Some drugs used in the treatment of narcolepsy are classified here.
Nootropics are classified in N06BX.
Clonidine and guanfacine also used in ADHD are classified in C02AC.

N06BA - Centrally Acting Sympathomimetics

Amfetamine is classified in this group, see comment under A08AA - Centrally acting antiobesity products.

Since atomoxetine is approved for use both in children, adolescents and in adults, the DDD is based on the treatment of a 70 kg person. The majority of the users will, however, probably be under 18 years of age.

N06BA12 - Lisdexamfetamine
DoseRoute of administrationNote
2020 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home